Undoubtedly, further research on the use of DPP-4 inhibitors in the treatment of GDM and their possible impact on reducing fetal programming for obesity and metabolic diseases. The gene discussed is DPP4; the disease is obesity due to melanocortin 4 receptor deficiency.